IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3909
Positioning
Market Dominance
Manufacturing
Medical Equipment
$2M
Michael Myers
Quoin Pharmaceuticals, Ltd. focuses on the development of therapeutic products for rare and orphan diseases. It offers QRX003, a topical lotion to treat Netherton Syndrome; QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$QNRX Quoin Pharmaceuticals, Ltd. | 37 | 30 | 22 | 68 | - | - | -651.4% | -214.9% | - | - | - | - | 0.0% | - | $2M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Quoin Pharmaceuticals, Ltd. (QNRX) receives a "Avoid" rating with a composite score of 37.0/100. It ranks #3909 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Direct cash return
Michael Myers
Chief Executive Officer
Labor Force
4
30
25
9
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for QNRX
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
No analyst ratings for QNRX.
View All RatingsInsufficient data for Financial Analysis
ROE proxy -651.4% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Quoin Pharmaceuticals, Ltd. with an Avoid rating, assigning a composite score of 37.0/100 and 1 out of 5 stars. Ranked #3909 of 7,333 stocks, QNRX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
QNRX's quality score of 30/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -651.4% (sector avg: -2.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
QNRX registers a value score of just 22/100, suggesting the stock trades at a significant premium to its fundamental metrics. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Quoin Pharmaceuticals, Ltd.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -214.9% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
QNRX demonstrates moderate momentum with a score of 68/100, suggesting a neutral price trend without strong directional conviction. Revenue growth data is not currently available, while a beta of 92.91 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
Quoin Pharmaceuticals, Ltd. registers a low stability score of 9/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 92.91. Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
The short interest score of 50/100 for QNRX suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 92.91), micro-cap liquidity risk. With a $2M market cap (micro-cap), Quoin Pharmaceuticals, Ltd. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Quoin Pharmaceuticals, Ltd. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3909 of 7,333 overall (47th percentile). Key comparisons include ROE of -651.4% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While QNRX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (9) would have the largest impact on the composite score.
ROE 26166% ABOVE SECTOR MEDIAN (FAVORABLE)
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Quoin Pharmaceuticals, Ltd. (QNRX) as Avoid with a composite score of 37.0/100 at a current price of $8.73. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (68th percentile) and quality (30th percentile), which together account for the majority of the composite score. Offsetting weakness in stability (9th percentile) and value (22th percentile) tempers our overall conviction. We assign a No Moat rating (20/100), High uncertainty, and Poor capital allocation.
Key items to watch: valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Quoin Pharmaceuticals, Ltd. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 37.0/100 places it at rank #3909 in our full 7,333-stock universe. At $2M in market capitalization, Quoin Pharmaceuticals, Ltd. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (68th percentile) are constructive regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for Quoin Pharmaceuticals, Ltd., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $8.73, Quoin Pharmaceuticals, Ltd. is trading at a premium to fundamental value. Our value factor score of 22/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
Valuation multiples are not available for this company, which limits our ability to assess relative pricing. We rely more heavily on factor-based valuation signals in such cases.
Positive momentum (68th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
The Avoid rating (composite 37.0/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Below-average quality (30th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
High beta of 92.91 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
We assign a High uncertainty rating to Quoin Pharmaceuticals, Ltd.. Key risk factors include elevated market sensitivity (beta of 92.91), below-average price stability (9th percentile), weak quality scores (30th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 92.91); below-average price stability (9th percentile); weak quality scores (30th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 9th percentile and quality factor at the 30th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate Quoin Pharmaceuticals, Ltd.'s capital allocation as Poor. Key concerns include low returns on equity (-651.4%), weak asset returns (ROA -214.9%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Quoin Pharmaceuticals, Ltd. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Quoin Pharmaceuticals, Ltd. receives a Avoid rating with a composite score of 37.0/100 (rank #3909 of 7,333). Our quantitative framework assigns a No Moat (20/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 31/100.
Our analysis does not support a constructive view on Quoin Pharmaceuticals, Ltd. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Quoin Pharmaceuticals, Ltd. a meaningful economic moat, scoring 20/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and growth durability (7/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Rev growth N/A, 5yr history. These pillars form the core of Quoin Pharmaceuticals, Ltd.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and financial resilience (0.8/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Quoin Pharmaceuticals, Ltd.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 30/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -651.4% and ROA of -214.9%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -651.4% compares to a sector median of -2.5%.
Balance sheet data is limited, restricting our assessment of financial resilience. Investors should seek additional disclosure on leverage and liquidity before forming a complete view of financial health.
Above 50MA
37.18%
Net New Highs
+51081
Quoin Pharmaceuticals (QNRX) stock surged by approximately 157% after announcing a $104.5 million funding deal, which includes an initial cash infusion to support the clinical development of its lead candidate, QRX003, for Netherton Syndrome. This significant financial backing, combined with regulatory designations like Orphan Drug status and a Breakthrough Medicine Designation application for QRX003, suggests strong investor confidence in the company's rare disease pipeline and its potential market impact. The company is actively progressing with clinical trials and has a distribution partnership for market entry in the MENA region, further enhancing its prospects.
Quoin Pharmaceuticals (NASDAQ: QNRX) has filed for Breakthrough Medicine Designation with the Saudi Food and Drug Authority (SFDA) for QRX003, its topical treatment for Netherton Syndrome. If granted, this designation could lead to accelerated review and potential market availability in Saudi Arabia by the second half of 2026, marking the first-ever approved treatment for Netherton Syndrome globally. The company also expects to complete enrollment for two pivotal clinical trials in 1H 2026, with top-line data anticipated in 2H 2026, and plans for NDA submissions in late 2026/early 2027.
Quoin Pharmaceuticals (NASDAQ: QNRX) has successfully achieved target topical rapamycin loadings of 4% w/w in a proprietary lotion and 5% w/w in a dermal patch. The company plans to manufacture clinical trial and stability batches in Q4 2025 and begin clinical testing in multiple indications, including microcystic lymphatic malformations and venous malformations, in 1H 2026. This milestone is a significant step forward, as there are currently no FDA-approved treatments for these target indications.
Quoin Pharmaceuticals (NASDAQ: QNRX) provided a corporate update and Q3 2025 results on November 6, 2025, detailing a private placement financing up to $105.3 million and a cash position of $5.4 million as of September 30, 2025, expected to fund operations into 2027. The company announced that QRX003 received FDA Orphan Drug designation for Netherton Syndrome, with pivotal enrollment for the drug scheduled to begin in Q4 2025, alongside an expanded pediatric program. Additionally, Sally Lawlor was appointed CFO, and the "NETHERTON NOW" awareness campaign reached over 1.5 million video views.
Quoin Pharmaceuticals announced that the U.S. FDA has granted Orphan Drug Designation for its lead product candidate, QRX003, for the treatment of Netherton Syndrome. This designation provides benefits such as tax credits and market exclusivity if approved, following a previous EMA orphan designation. QRX003 is currently in late-stage pivotal clinical trials, with enrollment expected to complete in Q1 2026 and an NDA submission planned for later in 2026.